We’re double upgrading Eli Lilly after the CEO and other insiders scoop up the slumping stock
An effective hand Lilly groups from inside, the obesity collected the shares of the drug producer-a great show of trust that heated up to the beaten shares. Accordingly, we return Lilly to our equivalent to 1 degree from 3. Although not for our trade restrictions, we will take at least some of the $ 774 shares in the late July before crushing the trial data that creates frustration for the obesity pill, which is estimated to be hot. This was the main reason why we reduced Lilly to 3 last week on the day of the second quarter gain report. However, investing is about having strong views that you keep completely loose – and when the facts change or when new information appears, you must be ready to change your view. Now that’s the case for Lilly. Last night we received new information in a series of applications with the securities and the stock market commission. Eli Lilly CEO David Ricks and four other people in the company – the other two managers and two members of the board of directors – purchased additional shares in the company. SEC Dosyalarına göre satın alımlar aşağıdaki gibidir: Ricks: 1.052,263.01 (ortalama 644.769 $) baş bilimsel memur Daniel Skovronsky: 634.769 $ ‘lık 1.632 hisse: 634.405 $ (ortalama 634.40 $ ° C (78.22.22.22.22.22.25.2. 627.01 $ ‘LIKE) Director Fyrwald: $ 1.005,242.35 ($ 642.32738) Director Gabrielle Sulzberger: 75.018.294 ($ 117 $ 117 shares 641.182) why we discussed and purchased the executives of the managers and the managers. It is an important thing to do by investors: There is a single reason to finance a lot of reasons for selling a stock. It is particularly remarkable that the Fyrwald is the CEO of the CEO, instead of the CEO of the CEO, instead of the CEO. There is no denying that a challenging investor may not be able to enter a little bit of a well -known company. It has nothing to do with everything that he believes in, he has nothing to do with the Sunday. You will receive a trade warning before you buy a shareholder in its portfolio. There is no confidence or a task for receiving any information.
